When reminiscing about sports moments and personalities of days gone by, the familiar anecdotes are often a joy to hear again and again. Even better, though, is when there are fresh new stories to be ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min DraftKings will move its ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Hasbro's plan is to open its new office in the Boston Seaport by the end of 2026 The temporary office will also be in the Seaport A Hasbro spokeswoman wouldn't say if the temporary office is open to ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Jeffrey is a freelance features writer at Collider. He is an MPA-accredited entertainment journalist and a Tomatometer-approved critic based in the LA area. He graduated from the University of Texas ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Boston Harbor Hotel is ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...